


Nirmatrelvir/ritonavir (Paxlovid™) Nursing Administration Information

Indication

- Nirmatrelvir/ritonavir (Paxlovid™) is an antiviral medication that has been approved by Health Canada for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death
- Taking nirmatrelvir/ritonavir (Paxlovid™) does not change isolation requirements for residents with COVID-19
- Nirmatrelvir/ritonavir (Paxlovid™) has a number of contraindications and drug interactions so thorough resident screening by the prescriber and a pharmacist occurs prior to prescribing and dispensing
- The PCH prescriber may need to adjust some of the resident's other medications during the time they are on the nirmatrelvir/ritonavir (Paxlovid™) and for a 3-5 days after the treatment is complete (e.g. holding doses, dose increases, or dose decreases)


Supplied

- Paxlovid™ contains two antiviral medicines co-packaged together - nirmatrelvir 150 mg (pink tablets) and ritonavir 100 mg (white tablets)
- Nirmatrelvir/ritonavir (Paxlovid™) is supplied from the manufacturer in boxes containing five blister cards each. Each blister card contains all the medication required for one day of treatment and each box contains all the medication required for a five day treatment course.
- The blister card is divided into two sections, a *Morning Dose* section (the yellow left half side of the blister card) and an *Evening Dose* section (the blue right half side of the blister card)
- Each section of the blister card contains two pink nirmatrelvir 150 mg tablets and one white ritonavir 100 mg tablet



Dosage

- Nirmatrelvir/ritonavir (Paxlovid™) is administered orally every 12 hours for 5 days. The dosage of nirmatrelvir depends on renal function. The dosage of ritonavir remains the same, regardless of renal function.
- Usual dose: nirmatrelvir 2 x 150 mg po q12h and ritonavir 100 mg po q12h for 5 days
- Renal dosing: nirmatrelvir 1 x 150 mg po q12h and ritonavir 100 mg q12h daily for 5 days
- Transcribe the dose prescribed or pharmacist-adjusted dose on to the resident's medication administration record (MAR)
- For the renal dosing, the dispensing pharmacy will remove 1 nirmatrelvir 150 mg tablet from both dosing sections of the blister cards. The carton and each blister card will have a sticker affixed to identify that the dispensing pharmacy has altered the packaging and tablets have been removed to provide the recommended renal dosing.



Moderate Renal Impairment Dosing
Morning Dose: Take one nirmatrelvir tablet with one ritonavir tablet at the same time from the morning dose portion of the blister card. (left half yellow side)

Evening Dose: Take one nirmatrelvir tablet with one ritonavir tablet at the same time from the evening dose portion of the blister card. (right half blue side)

This package has been altered to accommodate your dose.

Nirmatrelvir/ritonavir (Paxlovid™) Nursing Administration Information

Administration

- The nirmatrelvir and ritonavir tablets MUST be given together every 12 hour for 5 days
- Both nirmatrelvir and ritonavir tablets can be taken with or without food
- The tablets must be swallowed whole. They cannot be crushed, halved or chewed.
- If the resident is unable to take the tablets whole, please contact the PCH prescriber
- The tablets cannot be administered via an enteral feeding tube



Usual Dose

- When the morning dose is due: Remove and administer the two nirmatrelvir 150 mg tablets (total dose 300 mg) and the single ritonavir 100 mg tablet from the *Morning Dose (yellow)* section of the blister card
- When the evening dose is due: Remove and administer the two nirmatrelvir 150 mg tablets (total dose 300 mg) and the single ritonavir 100 mg tablet from the *Evening Dose (blue)* section of the blister card



Renal Dose

- When the morning dose is due: Remove and administer the single nirmatrelvir 150 mg tablet and the single ritonavir 100 mg tablet from the *Morning Dose (yellow)* section of the blister card
- When the evening dose is due: Remove and administer the single nirmatrelvir 150 mg tablet and the single ritonavir 100 mg tablet from the *Evening Dose (blue)* section of the blister card

Missed Doses

- If it has been less than 8 hours since the missed dose, give the missed dose.
- If it has been more than 8 hours since the missed dose, do not give the missed dose. Discard these tablets in the pharmaceutical waste and resume administration at the next scheduled dosing time.
- Do not double the dose to make up for a missed dose.
- Give all of the doses of nirmatrelvir and ritonavir, even if the resident is feeling better.

Monitoring

- Nirmatrelvir/ritonavir (Paxlovid™) is generally well tolerated and most people experience mild side effects
- **Possible side effects may include*:**
 - *As this is a new medication, other side effects are possible and are still being identified
 - ◇ Altered sense of taste
 - ◇ Diarrhea
 - ◇ Vomiting
 - ◇ Headache
 - ◇ Muscle aches
 - ◇ High blood pressure
- Nirmatrelvir/ritonavir (Paxlovid™) interacts with many medications so the prescriber may need to adjust or monitor other medications to manage these interactions for the duration of the treatment and for 3-5 days after the treatment is complete

Paxlovid™ Product Monograph: <https://covid-vaccine.canada.ca/info/pdf/paxlovid-pm-en.pdf>
Paxlovid™ Patient Information Sheet:
English: <https://sharedhealthmb.ca/files/covid-19-paxlovid-patient-info.pdf>
French: <https://sharedhealthmb.ca/files/covid-19-paxlovid-patient-info-fr.pdf>